| scholarly article | Q13442814 |
| P50 | author | Ritsuko Komaki | Q64585410 |
| Ignacio I Wistuba | Q74766086 | ||
| Roy S. Herbst | Q89006575 | ||
| P2093 | author name string | Paul D Smith | |
| Michael S O'Reilly | |||
| Juliane M Jürgensmeier | |||
| Osamu Takahashi | |||
| B Nebiyou Bekele | |||
| Anderson Ryan | |||
| Baruch Erez | |||
| Jörg J Jacoby | |||
| Maria V Korshunova | |||
| Anna Biernacka | |||
| Keiko Hosho | |||
| P2860 | cites work | EGFR mutation and resistance of non-small-cell lung cancer to gefitinib | Q27824829 |
| Cancer statistics, 2010 | Q27860525 | ||
| Phase III trial of FOLFOX plus bevacizumab or cediranib (AZD2171) as first-line treatment of patients with metastatic colorectal cancer: HORIZON III. | Q46128004 | ||
| The tyrosine kinase inhibitor cediranib blocks ligand-induced vascular endothelial growth factor receptor-3 activity and lymphangiogenesis | Q46535751 | ||
| High expression of ErbB family members and their ligands in lung adenocarcinomas that are sensitive to inhibition of epidermal growth factor receptor | Q46853185 | ||
| Mutations of ras genes distinguish a subset of non-small-cell lung cancer cell lines from small-cell lung cancer cell lines | Q46937946 | ||
| 2010 Society for Neuro-Oncology Annual Meeting: a report of selected studies | Q51159183 | ||
| MAPK and PI3K signalling differentially regulate angiogenic and lymphangiogenic cytokine secretion in squamous cell carcinoma of the head and neck. | Q54633150 | ||
| ERK-MAPK signaling opposes Rho-kinase to promote endothelial cell survival and sprouting during angiogenesis | Q58001185 | ||
| Cediranib Plus FOLFOX/CAPOX Versus Placebo Plus FOLFOX/CAPOX in Patients With Previously Untreated Metastatic Colorectal Cancer: A Randomized, Double-Blind, Phase III Study (HORIZON II) | Q58023765 | ||
| ras gene mutations in non-small cell lung cancers are associated with shortened survival irrespective of treatment intent | Q68254101 | ||
| Effects of pharmacologic antagonists of epidermal growth factor receptor, PI3K and MEK signal kinases on NF-kappaB and AP-1 activation and IL-8 and VEGF expression in human head and neck squamous cell carcinoma lines | Q78052005 | ||
| Randomized phase II study of bevacizumab in combination with chemotherapy in previously untreated extensive-stage small-cell lung cancer: results from the SALUTE trial | Q83897319 | ||
| Global cancer statistics, 2002 | Q27860562 | ||
| Tumor angiogenesis: therapeutic implications | Q27860595 | ||
| Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma | Q27860881 | ||
| Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib | Q27861059 | ||
| AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer | Q28251373 | ||
| Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer | Q28278736 | ||
| Erlotinib in previously treated non-small-cell lung cancer | Q29547546 | ||
| Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo | Q29614729 | ||
| Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer | Q29618155 | ||
| Activation of MAP kinase kinase is necessary and sufficient for PC12 differentiation and for transformation of NIH 3T3 cells | Q29618480 | ||
| Transformation of mammalian cells by constitutively active MAP kinase kinase | Q29618686 | ||
| Phase III randomized trial comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma | Q30661157 | ||
| Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma | Q33990834 | ||
| Identification of common predictive markers of in vitro response to the Mek inhibitor selumetinib (AZD6244; ARRY-142886) in human breast cancer and non-small cell lung cancer cell lines | Q34129528 | ||
| New driver mutations in non-small-cell lung cancer | Q34161395 | ||
| Knockdown of oncogenic KRAS in non-small cell lung cancers suppresses tumor growth and sensitizes tumor cells to targeted therapy | Q34701196 | ||
| Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy | Q34743875 | ||
| Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil | Q34935734 | ||
| Targeted therapy against VEGFR and EGFR with ZD6474 enhances the therapeutic efficacy of irradiation in an orthotopic model of human non-small-cell lung cancer | Q36296482 | ||
| Treatment with HIF-1alpha antagonist PX-478 inhibits progression and spread of orthotopic human small cell lung cancer and lung adenocarcinoma in mice | Q37195150 | ||
| Growth-inhibitory and antiangiogenic activity of the MEK inhibitor PD0325901 in malignant melanoma with or without BRAF mutations | Q37269341 | ||
| Identifying genotype-dependent efficacy of single and combined PI3K- and MAPK-pathway inhibition in cancer | Q37376100 | ||
| Randomized, double-blind trial of carboplatin and paclitaxel with either daily oral cediranib or placebo in advanced non-small-cell lung cancer: NCIC clinical trials group BR24 study | Q37633813 | ||
| Personalized Medicine in Non–Small-Cell Lung Cancer: Is KRAS a Useful Marker in Selecting Patients for Epidermal Growth Factor Receptor–Targeted Therapy? | Q37797818 | ||
| Treatment of Non–Small-Cell Lung Cancer with Erlotinib or Gefitinib | Q37851148 | ||
| Assessing the Activity of Cediranib, a VEGFR-2/3 Tyrosine Kinase Inhibitor, against VEGFR-1 and Members of the Structurally Related PDGFR Family | Q39569822 | ||
| KRAS mutant lung cancer cells are differentially responsive to MEK inhibitor due to AKT or STAT3 activation: implication for combinatorial approach | Q39720116 | ||
| Effects of combined inhibition of MEK and mTOR on downstream signaling and tumor growth in pancreatic cancer xenograft models | Q39763382 | ||
| AZD6244 enhances the anti-tumor activity of sorafenib in ectopic and orthotopic models of human hepatocellular carcinoma (HCC). | Q39775573 | ||
| The mitogen-activated protein/extracellular signal-regulated kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) enhances the radiation responsiveness of lung and colorectal tumor xenografts | Q39785350 | ||
| AZD6244 (ARRY-142886), a potent inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase 1/2 kinases: mechanism of action in vivo, pharmacokinetic/pharmacodynamic relationship, and potential for combination in precl | Q40093939 | ||
| Biological characterization of ARRY-142886 (AZD6244), a potent, highly selective mitogen-activated protein kinase kinase 1/2 inhibitor | Q40164535 | ||
| Targeted therapy of orthotopic human lung cancer by combined vascular endothelial growth factor and epidermal growth factor receptor signaling blockade | Q40169795 | ||
| Tumor cell and endothelial cell therapy of oral cancer by dual tyrosine kinase receptor blockade | Q40497222 | ||
| Development of an orthotopic model to study the biology and therapy of primary human lung cancer in nude mice. | Q40610841 | ||
| Overall survival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL) | Q42073978 | ||
| Safety and efficacy of first-line bevacizumab-based therapy in advanced non-squamous non-small-cell lung cancer (SAiL, MO19390): a phase 4 study. | Q42669075 | ||
| A Phase II, Open-Label, Randomized Study to Assess the Efficacy and Safety of AZD6244 (ARRY-142886) Versus Pemetrexed in Patients with Non-small Cell Lung Cancer Who Have Failed One or Two Prior Chemotherapeutic Regimens | Q42673662 | ||
| Treatment-emergent hypertension and outcomes in patients with advanced non-small-cell lung cancer receiving chemotherapy with or without the vascular endothelial growth factor receptor inhibitor cediranib: NCIC Clinical Trials Group Study BR24. | Q43081790 | ||
| Dependence on phosphoinositide 3-kinase and RAS-RAF pathways drive the activity of RAF265, a novel RAF/VEGFR2 inhibitor, and RAD001 (Everolimus) in combination | Q43177478 | ||
| AZD6244 (ARRY-142886) enhances the antitumor activity of rapamycin in mouse models of human hepatocellular carcinoma. | Q43184161 | ||
| Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial. | Q46027726 | ||
| P433 | issue | 6 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | lung cancer | Q47912 |
| tumor angiogenesis | Q110495869 | ||
| P304 | page(s) | 1641-1654 | |
| P577 | publication date | 2012-01-24 | |
| P1433 | published in | Clinical Cancer Research | Q332253 |
| P1476 | title | Combined MEK and VEGFR inhibition in orthotopic human lung cancer models results in enhanced inhibition of tumor angiogenesis, growth, and metastasis | |
| P478 | volume | 18 |
| Q93348811 | An orthotopic non-small cell lung cancer model for image-guided small animal radiotherapy platforms |
| Q43515124 | Anti-tumour and anti-vascular effects of cediranib (AZD2171) alone and in combination with other anti-tumour therapies |
| Q35754265 | Antitumor activity of the MEK inhibitor trametinib on intestinal polyp formation in Apc(Δ716) mice involves stromal COX-2. |
| Q38997663 | Aquaporin 3 knockdown suppresses tumour growth and angiogenesis in experimental non-small cell lung cancer |
| Q90169736 | Co-delivery of VEGF siRNA and Etoposide for Enhanced Anti-angiogenesis and Anti-proliferation Effect via Multi-functional Nanoparticles for Orthotopic Non-Small Cell Lung Cancer Treatment |
| Q28547364 | Combinational Therapy Enhances the Effects of Anti-IGF-1R mAb Figitumumab to Target Small Cell Lung Cancer |
| Q55081687 | Contrast-enhanced computed tomography combined with Chitosan-Fe3O4 nanoparticles targeting fibroblast growth factor receptor and vascular endothelial growth factor receptor in the screening of early esophageal cancer. |
| Q36047366 | Effects of tumor microenvironment heterogeneity on nanoparticle disposition and efficacy in breast cancer tumor models |
| Q36184584 | Genetic and biochemical alterations in non-small cell lung cancer |
| Q35955383 | Immunoglobulin-like transcript 4 promotes tumor progression and metastasis and up-regulates VEGF-C expression via ERK signaling pathway in non-small cell lung cancer |
| Q47769437 | In vivo antitumor effect of endostatin-loaded chitosan nanoparticles combined with paclitaxel on Lewis lung carcinoma |
| Q27313653 | Landscape of Targeted Anti-Cancer Drug Synergies in Melanoma Identifies a Novel BRAF-VEGFR/PDGFR Combination Treatment |
| Q26824599 | Molecular testing in lung cancer in the era of precision medicine |
| Q38104670 | Molecular‐targeted agents combination therapy for cancer: Developments and potentials |
| Q41815541 | NF1 deletion generates multiple subtypes of soft-tissue sarcoma that respond to MEK inhibition. |
| Q37203714 | Pancreatic cancer-associated stellate cells promote differentiation of myeloid-derived suppressor cells in a STAT3-dependent manner |
| Q45937494 | Rational combination therapy with PARP and MEK inhibitors capitalizes on therapeutic liabilities in RAS mutant cancers. |
| Q54976863 | Repurposing sertraline sensitizes non-small cell lung cancer cells to erlotinib by inducing autophagy. |
| Q38663069 | Selumetinib for the treatment of non-small cell lung cancer |
| Q38836927 | Selumetinib in the treatment of non-small-cell lung cancer |
| Q39466460 | Selumetinib: A Promising Pharmacologic Approach for KRAS -Mutant Advanced Non-Small-Cell Lung Cancer |
| Q36291134 | Synergistic anti-tumor activity and inhibition of angiogenesis by cotargeting of oncogenic and death receptor pathways in human melanoma |
| Q38740315 | Targeting the MEK signaling pathway in non-small cell lung cancer (NSCLC) patients with RAS aberrations |
| Q53358684 | The prognostic significance of growth factors and growth factor receptors in gastric adenocarcinoma |
| Q39186300 | Tumor VEGF:VEGFR2 autocrine feed-forward loop triggers angiogenesis in lung cancer. |
| Q93053622 | UDP-glucose accelerates SNAI1 mRNA decay and impairs lung cancer metastasis |
| Q39025641 | Utility and applications of orthotopic models of human non-small cell lung cancer (NSCLC) for the evaluation of novel and emerging cancer therapeutics |
| Q38041720 | Vertical Pathway Targeting in Cancer Therapy |
| Q38969283 | p90/CIP2A mediates breast cancer cell proliferation and apoptosis |
Search more.